Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host

Gene Therapy

Volumn 3, Issue 6, 1996, Pages 521-530

  Poller, W ^a,b   Schneider Rasp, S ^a   Liebert, U ^b,c   Merklein, F ^a   Thalheimer, P ^a   Haack, A ^a,d   Schwaab, R ^d   Schmitt, C ^d   Brackmann, H H ^d  

^a University Clinical Centre   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

CD4+ helper T cell depletion; E3 region functions; Replication deficient adenoviral vectors; Transgene stability

Indexed keywords

BLOOD CLOTTING FACTOR 9; CD4 ANTIGEN; LUCIFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CASE REPORT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; GENE TRANSFER; GENETIC STABILITY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA PRIMERS; ENDOTHELIUM, VASCULAR; FACTOR IX; GENE EXPRESSION; GENES, MHC CLASS I; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS; TRANSFECTION; UMBILICAL VEINS;

EID: 0030005390     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Rosenfeld M et al. Increasing expression of the normal human CFTR cDNA in cystic fibrosis epithelial cells results in a progressive increase in the level of CFTR protein expression, but a limit on the level of cAMP-stimulated chloride secretion. Hum Gene Ther 1994; 5: 1121-1129.
2. Bout A et al. In vivo adenovirus-mediated transfer of human CFTR cDNA to Rhesus monkey airway epithelium: efficacy, toxicity and safety. Gene Therapy 1994; 1: 385-394.
3. Herz J, Gerard R. Adenovirus-mediated transfer of the low-density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816.
4. Ishibashi S et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
5. Mouiller P et al. Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int 1994; 45: 1220-1225.
6. Barr E et al. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Therapy 1994; 1: 51-58.
7. Ghadge G et al. CNS delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Therapy 1995; 2: 132-137.
8. Zhang W-W et al. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gem Ther 1995; 6: 155-164.
9. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
10. Engelhardt J, Ye X, Doranz B, Wilson J. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
11. Engelhardt J, Litzky L, Wilson J. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994; 5: 1217-1229.
12. Stratford-Perricaudet L et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-256.
13. Kass-Eisler A et al. The impact of developmental stage, route of administration and the immune system on adenovinis-mediated gene transfer. Gene Therapy 1994; 1: 395-402.
14. Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
15. Wold W, Goodling L. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991; 184: 1-8.
16. Ginsberg H et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991; 88: 1651-1655.
17. Korner H, Fritzsche U, Burgert H-G. Tumor necrosis factor stimulates expression of adenovirus early region 3 proteins: implications for viral persistence. Proc Natl Acad Sci USA 1992; 89: 11857-11861.
18. Lee M, Abina M, Haddada H, Perricaudet M. The constitutive expression of the immunomodulatory gp19k protein in E1-E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Therapy 1995; 2 256-262.
19. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
20. Smith T et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
21. Kay M et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in haemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357.
22. Cosimi A Future of monoclonal antibodies in solid organ transplantation. Dig Dis Sci 1995; 40: 65-72.
23. Qin S et al. 'Infectious' transplantation tolerance. Science 1993; 259: 974-977.
24. Meiser B et al. Chimeric monoclonal CD4 antibody - a novel immunosuppressant for clinical heart transplantation. Transplantation 1994; 58: 419-423.
25. Ludwig M et al. Hemophilia caused by five different nondeletion mutations in the protease domain of factor IX. Blood 1992; 79: 1225-1232.
26. Ludwig M, Grimm T, Brackmann H, Olek K. Parental origin of factor IX gene mutations, and their distribution in the gene. Am J Hum Genet 1992; 50: 164-173.
27. Cox J et al. Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 1990; 247: 715-718.
28. Williams J et al. Lymphoid specific gene expression of the adenovirus early region 3 promoter is mediated by NF-kappaB binding motifs. EMBO J 1990; 9: 4435-4442.
29. Ginsberg H et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 1989; 86: 3823-3827.
30. Gooding L et al. The 10 400- and 14 500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J Virol 1991; 65: 4114-4123.
31. Tanaka Y, Tevethia S. Differential effect of adenovirus 2 E3/19k glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated cytolysis. Virology 1988; 165: 357-366.
32. Marrack P, Kappler J. Subversion of the immune system by pathogens. Cell 1994; 76: 323-332.
33. Yang Y, Li Q, Ertl H, Wilson J. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69-2004-2015.
34. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy of cystic fibrosis. Nat Genet 1994; 7: 362-369.
35. Brutkiewicz R, Welsh R. Major histocompatibility complex class 1 antigens and the control of viral infections by natural killer cells. J Virol 1995; 69: 3967-3971.
36. + CTLs in vivo. J Immunol 1995; 155: 2564-2570.
37. Pearson T et al. The assessment of transplantation tolerance induced by anti-CD4 monoclonal antibody in the murine model. Transplantation 1993; 55: 361-367.
38. Volk H-D et al. Tolerance induction by anti-CD4 MAb treatment in a rat kidney transplantation model. Transplant Proc 1994; 26: 3155-3156.
39. Yang Y, Trinchieri G, Wilson J. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995; 1: 890-893.
40. Wilson C, Kay M. Immunomodulation to enhance gene therapy. Nat Med 1995; 1: 887-889
41. Cosimi A et al. Prolonged survival of nonhuman primate renal allograft hosts treated only with anti-CD4 monoclonal antibody. Surgery 1990; 108: 406-414.
42. Darby C, Morris P, Wood K. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4T T cells. Transplantation 1992; 54: 483-490.
43. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning. Cold Spring Harbor Laboratory: Cold Spring Harbor, 1989.
44. Draijer R et al. Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin. Circ Res 1995; 77: 897-905.
45. Kriegler M (ed). Gene Transfer and Expression. Freeman: New-York, 1990.
46. Niewiesk S et al. Susceptibility to measles-induced encephalitis in mice correlates with impaired antigen presentation to CTL. J Virol 1993; 67: 75-81.
47. Liebert U et al. Characterization of measles virus-induced cellular autoimmune reactions against myelin basic protein in Lewis rats. J Neuroimmunol 1990; 64: 706-713.